A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Y. K. Kang, S. Y. Rha, P. Tassone, J. Barriuso, R. Yu, T. Szado, A. Garg, Y. J. Bang

Research output: Contribution to journalArticlepeer-review

62 Citations (Scopus)

Fingerprint Dive into the research topics of 'A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences